Oral anticoagulation therapy in the primary care setting

Harefuah

Volumn 132, Issue 11, 1997, Pages

  Vinker, Shlomo ^a   Nakar, Sasson ^a   Finkel, Sergei ^a   Nir, Emanuel ^a   Hyam, Eitan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; ANTICOAGULANT AGENT; BEZAFIBRATE; DIPYRIDAMOLE; WARFARIN;

ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; PRIMARY MEDICAL CARE; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG INTERACTIONS; DRUG MONITORING; FAMILY PRACTICE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 0030969836     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ansell JE, Oral anticoagulant therapy - 50 years later. Arch Int Med, 1993; 153: 586-96.
2. van der Meer FJM, Rosendaal FR, Vandenbroucke JP & Briet E, Bleeding complications in oral anticoagulant therapy, an analysis of risk factors. Arch Int Med, 1993; 153: 1557-62.
3. Fihn SD, McDonell M, Martin D & al, Risk factors for complications of chronic anticoagulation, a multicenter study. Am Coll Physic, 1993; 118: 511-20.
4. Fihn SD, Aiming for safe anticoagulation. N Engl J Med, 1995; 333: 54-55.
5. Warfarin Sodium. In: Martindale the Extra Pharmacopoeia, 31 edition, Reynolds JEF, Royal Pharmaceutical Society, London 1996; 965-72.
6. Atrial fibrillation investigators: atrial fibrillation, aspirin, anticoagulation study. Boston Area Anticoagulation Trial for Atrial Fibrillation Study, Canadian Atrial Fibrillation Anticoagulation Study, Stroke Prevention in Atrial Fibrillation Study, Veterans Affairs Stroke Prevention in non Rheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Int Med, 1994; 154: 1449-57.
7. Albers GW, Laboratory monitoring of oral anticoagulant therapy: are we being misled? Neurology, 1993; 43: 468-70.
8. Rose PE, On behalf of the BCSH Hemostasis and Thrombosis Task Force of the British Society for Haematology. J Clin Pathol, 1993; 46: 1069-70.
9. Forth ACCP Consensus Conference on Antithrombotic Therapy. Chest, 1995; 108 (suppl): 225S-522S.
10. The European Atrial Fibrillation Trial Study Group, Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med, 1995; 333: 5-10.
11. Cannegieter SC, Rosendaal FR, Wintzen AR & al, Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med, 1995; 333: 11-7.
12. Taylor FC, Ramasay WE, Renton A & Cohen H, Methods for managing the increased workload in anticoagulant clinics. BMJ, 1996; 312: 286.
13. Fitzmaurice DA & Murray JA, Monitoring oral anticoagulation in primary care-quality assurance and computerized decision support will help to minimize inconsistencies. BMJ, 1996; 312: 1431-2.
14. Gurwitz JH, Avron J, Ross-Degnan D & al, Aging and the anticoagulant response to warfarin therapy. Ann Int Med, 1992; 116: 901-4.
15. Brigden ML, When bleeding complicates oral anticoagulant therapy, how to anticipate, investigate, and treat. Postgraduate Med, 1995; 98: 153-68.
16. Dahl T, Abildgaard U & Sandset PM, Long term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit? J Int Med, 1995; 237: 323-9.